Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026)

Intellia Therapeutics has reported Change in Receivables over the past 11 years, most recently at -$337000.0 for Q1 2026.

  • Quarterly Change in Receivables fell 116.96% to -$337000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Mar 2026, up 94.7% year-over-year, with the annual reading at $951000.0 for FY2025, 103.4% up from the prior year.
  • Change in Receivables was -$337000.0 for Q1 2026 at Intellia Therapeutics, up from -$1.6 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $30.0 million in Q4 2023 and troughed at -$24.1 million in Q2 2024.
  • The 5-year median for Change in Receivables is -$29000.0 (2024), against an average of $417647.1.
  • Year-over-year, Change in Receivables skyrocketed 11850.98% in 2023 and then tumbled 16059.6% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$255000.0 in 2022, then skyrocketed by 11850.98% to $30.0 million in 2023, then tumbled by 101.12% to -$337000.0 in 2024, then crashed by 369.44% to -$1.6 million in 2025, then surged by 78.7% to -$337000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Change in Receivables are -$337000.0 (Q1 2026), -$1.6 million (Q4 2025), and -$303000.0 (Q3 2025).